Because most prostate cancers are not lethal, active surveillance is a desirable treatment option for patients presenting with localized prostate cancer, low prostate specific antigen (PSA) levels, and low risk according to the D’Amico risk category (see Supplemental Information for a brief review of this metric)2. Here, KLK3 is linked to prostate cancer.